325 related articles for article (PubMed ID: 29797007)
41. Clinical use of lentiviral vectors.
Milone MC; O'Doherty U
Leukemia; 2018 Jul; 32(7):1529-1541. PubMed ID: 29654266
[TBL] [Abstract][Full Text] [Related]
42. Detailed design and comparative analysis of protocols for optimized production of high-performance HIV-1-derived lentiviral particles.
Mitta B; Rimann M; Fussenegger M
Metab Eng; 2005; 7(5-6):426-36. PubMed ID: 16102993
[TBL] [Abstract][Full Text] [Related]
43. Robust Enhancement of Lentivirus Production by Promoter Activation.
Suzuki N; Yoshida T; Takeuchi H; Sakuma R; Sukegawa S; Yamaoka S
Sci Rep; 2018 Oct; 8(1):15036. PubMed ID: 30310119
[TBL] [Abstract][Full Text] [Related]
44. Generation of a genome scale lentiviral vector library for EF1α promoter-driven expression of human ORFs and identification of human genes affecting viral titer.
Škalamera D; Dahmer M; Purdon AS; Wilson BM; Ranall MV; Blumenthal A; Gabrielli B; Gonda TJ
PLoS One; 2012; 7(12):e51733. PubMed ID: 23251614
[TBL] [Abstract][Full Text] [Related]
45. Production and Concentration of Lentivirus for Transduction of Primary Human T Cells.
Kennedy A; Cribbs AP
Methods Mol Biol; 2016; 1448():85-93. PubMed ID: 27317175
[TBL] [Abstract][Full Text] [Related]
46. Production of Retrovirus-Based Vectors in Mildly Acidic pH Conditions.
Holic N; Fenard D
Methods Mol Biol; 2016; 1448():41-8. PubMed ID: 27317171
[TBL] [Abstract][Full Text] [Related]
47. The use of lentiviral vectors to obtain transgenic rats.
Remy S; Nguyen TH; Ménoret S; Tesson L; Usal C; Anegon I
Methods Mol Biol; 2010; 597():109-25. PubMed ID: 20013229
[TBL] [Abstract][Full Text] [Related]
48. High-titer lentiviral vectors stimulate fetal calf serum-specific human CD4 T-cell responses: implications in human gene therapy.
Bao L; Guo H; Huang X; Tammana S; Wong M; McIvor RS; Zhou X
Gene Ther; 2009 Jun; 16(6):788-95. PubMed ID: 19340017
[TBL] [Abstract][Full Text] [Related]
49. Optimized large-scale production of high titer lentivirus vector pseudotypes.
Sena-Esteves M; Tebbets JC; Steffens S; Crombleholme T; Flake AW
J Virol Methods; 2004 Dec; 122(2):131-9. PubMed ID: 15542136
[TBL] [Abstract][Full Text] [Related]
50. Characterization and comparative performance of lentiviral vector preparations concentrated by either one-step ultrafiltration or ultracentrifugation.
Papanikolaou E; Kontostathi G; Drakopoulou E; Georgomanoli M; Stamateris E; Vougas K; Vlahou A; Maloy A; Ware M; Anagnou NP
Virus Res; 2013 Jul; 175(1):1-11. PubMed ID: 23583684
[TBL] [Abstract][Full Text] [Related]
51. Scalable Lentiviral Vector Production Using Stable HEK293SF Producer Cell Lines.
Manceur AP; Kim H; Misic V; Andreev N; Dorion-Thibaudeau J; Lanthier S; Bernier A; Tremblay S; Gélinas AM; Broussau S; Gilbert R; Ansorge S
Hum Gene Ther Methods; 2017 Dec; 28(6):330-339. PubMed ID: 28826344
[TBL] [Abstract][Full Text] [Related]
52. Production of lentiviral vectors by large-scale transient transfection of suspension cultures and affinity chromatography purification.
Segura MM; Garnier A; Durocher Y; Coelho H; Kamen A
Biotechnol Bioeng; 2007 Nov; 98(4):789-99. PubMed ID: 17461423
[TBL] [Abstract][Full Text] [Related]
53. Lentiviral vector production, titration, and transduction of primary neurons.
Ding B; Kilpatrick DL
Methods Mol Biol; 2013; 1018():119-31. PubMed ID: 23681623
[TBL] [Abstract][Full Text] [Related]
54. Lentiviral vectors for delivery of genes into neonatal and adult ventricular cardiac myocytes in vitro and in vivo.
Zhao J; Pettigrew GJ; Thomas J; Vandenberg JI; Delriviere L; Bolton EM; Carmichael A; Martin JL; Marber MS; Lever AM
Basic Res Cardiol; 2002 Sep; 97(5):348-58. PubMed ID: 12200634
[TBL] [Abstract][Full Text] [Related]
55. Development of an Rev-independent, minimal simian immunodeficiency virus-derived vector system.
Pandya S; Boris-Lawrie K; Leung NJ; Akkina R; Planelles V
Hum Gene Ther; 2001 May; 12(7):847-57. PubMed ID: 11339901
[TBL] [Abstract][Full Text] [Related]
56. Advanced modular self-inactivating lentiviral expression vectors for multigene interventions in mammalian cells and in vivo transduction.
Mitta B; Rimann M; Ehrengruber MU; Ehrbar M; Djonov V; Kelm J; Fussenegger M
Nucleic Acids Res; 2002 Nov; 30(21):e113. PubMed ID: 12409472
[TBL] [Abstract][Full Text] [Related]
57. Manufacture of Third-Generation Lentivirus for Preclinical Use, with Process Development Considerations for Translation to Good Manufacturing Practice.
Gándara C; Affleck V; Stoll EA
Hum Gene Ther Methods; 2018 Feb; 29(1):1-15. PubMed ID: 29212357
[TBL] [Abstract][Full Text] [Related]
58. Titering lentiviral vectors: comparison of DNA, RNA and marker expression methods.
Sastry L; Johnson T; Hobson MJ; Smucker B; Cornetta K
Gene Ther; 2002 Sep; 9(17):1155-62. PubMed ID: 12170379
[TBL] [Abstract][Full Text] [Related]
59. [Pilot-scale preparation of clinical-grade third generation lentivirus].
Duan D; Ji Y; Zhou M; Gao J
Sheng Wu Gong Cheng Xue Bao; 2019 Jul; 35(7):1307-1316. PubMed ID: 31328487
[TBL] [Abstract][Full Text] [Related]
60. Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo.
Coleman JE; Huentelman MJ; Kasparov S; Metcalfe BL; Paton JF; Katovich MJ; Semple-Rowland SL; Raizada MK
Physiol Genomics; 2003 Feb; 12(3):221-8. PubMed ID: 12488511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
